ClinicalTrials.gg
TerminatedNCT03999580ViDiPeC-2Updated Oct 21, 2026

The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )

A Phase 3 interventional study of vitamin D3 in Crohn Disease, sponsored by Jantchou Prevost. Terminated at 7 sites in Canada. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Jantchou Prevost · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Enrollment stopped at 55 of 316 planned participants due to recruitment challenges related to the COVID-19 pandemic and funding constraints. All enrolled participants completed 52-week follow-up.
Updated Oct 21, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing cholecalciferol in Crohn Disease — none open to participants now, 2 under way, 1 of them phase 3. Cholecalciferol · Crohn Disease.

Enrollment
5th of 15
55 · median 43
Started
2020
with 1 other
Phase 3
3 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Jantchou Prevost

Among the 15 studies testing cholecalciferol in Crohn Disease, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 12th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 15 studies testing cholecalciferol in Crohn Disease is open now. The open studies under Crohn Disease, anywhere →

About cholecalciferol

Cholecalciferol: first FDA approval 2000 (INFUVITE ADULT), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing cholecalciferol in Crohn Disease as a file.
02

Study summary

The purpose of this study is to determine if vitamin D as an adjuvant therapy can improve the outcome (i.e. fewer relapses) and the quality of life, including levels of physical activity, in children diagnosed Crohn's disease (CD).

Read the detailed description

Crohn's disease is a chronic inflammatory condition affecting all segments of the digestive tract from the mouth to the anus. This condition is associated with an increased risk of relapses throughout the course of the disease. Nearly 25% of patients with Crohn's disease are in the pediatric age range. Many epidemiological data are in favor of an increase incidence of pediatric Crohn's disease. Environmental factors could explain this increased incidence. Among them sunlight exposure and vitamin D deficiency have been suggested by many authors.

Recent studies have described how varying doses of oral vitamin D supplementation can alter serum levels of 25 hydroxyvitamin D (25(OH)D), but no study has specifically addressed the question as to whether vitamin D supplementation can alter the rate of relapse/complications and/or quality of life in children diagnosed with CD.

Current treatments of CD at diagnosis are effective around the time of diagnosis, but in the short and long term, some of these therapies are inefficient or lead to allergic or intolerance reactions. Altogether the rate of relapses in the year after diagnosis is significant. Thus, different therapeutic approaches must be investigated with the aim of lowering the burden of the disease.

From November 2012 to July 2013, we conducted an open label pilot cohort study aiming to investigate the bioavailability and tolerance of high doses of vitamin D3 (3,000 IU or 4,000 IU per day) administered orally as an adjunct therapy in 20 children with newly diagnosed pediatric CD (http://clinicaltrials.gov/ct2/show/NCT01692808). Data from laboratory studies, observational research and pilot trials taken together suggest that vitamin D can be of great importance in the genesis and progression of CD. Vitamin D deficiency could be a true risk factor for disease occurrence and/or relapses. The results of our pilot study demonstrate that in children with active CD at diagnosis, a daily dose of 4,000 IU of vitamin D is well tolerated and quickly increases the blood levels of 25OHD3 to 100 nmol/L or above in 100% of children with CD at diagnosis. Moreover a maintenance dosage of 2,000 IU a day is required (and sufficient) for maintaining this target over several months. Currently there is no adequately powered study in the pediatric CD population exploring the relationship between vitamin D therapy at diagnosis and CD outcomes.

We propose a randomized controlled trial (RCT) to study the efficacy of high-dose oral vitamin D, as adjunct therapy, in children diagnosed CD, to reduce the relapse rate and to improve patients' quality of life.

Primary Efficacy End Point: The proportion of patient with at least one relapse 52 weeks after randomization.

Secondary efficacy endpoint: Quality of life scores, Cumulative steroid dose, Time to first relapse, Duration of corticotherapy, Number of relapses, Number of hospitalizations Safety Endpoint : incidence of hypercalcemia (defined as a corrected serum calcium level >2.65 mmol/L), incidence of hypercalciuria (defined as urinary calcium to creatinine molar ratio ≥1.50), incidence of supra-optimal levels of 25OHD3 as defined by a serum level ≥ 250 nmol/L, rate of study discontinuation due to hypercalcemia or hypercalciuria.

Efficacy Variable: Occurrence of relapse, Time to relapse, Change in QoL score from baseline to 26 weeks, 52 weeks. Change in physical activity score from baseline to 26 weeks, 52 weeks

03

Conditions studied

  • Crohn Disease

Keywords

  • Crohn
  • vitamin D
  • remission
  • inflammation
  • tolerance
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at randomization between 4 and 17 years inclusively
  2. Pediatric Crohn's Disease Activity Index (PCDAI) ≤ 10 with no clinical symptoms (abdominal pain or blood in the stool) at inclusion
  3. Receiving a stable dose for at least 4 weeks of any of the following drugs: Thiopurines, Methotrexate, or TNF-α inhibitors (Infliximab/Adalimumab)
  4. Dosage of fecal calprotectin lower than 250 µg/g stool at inclusion.

Exclusion criteria

Exclusion Criteria:

  1. History of surgery resulting in a permanent colostomy or ileostomy (because of the inability to calculate PCDAI at baseline)
  2. Patients who have already been included in the pilots vitamin D trials
  3. Patients actively enrolled in other CD drug trials.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Experimental Arm:

    Experimental: Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day 3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA).

    Drug: vitamin D3

  • Active comparator
    Control Arm:

    Active Comparator: Vitamin D3 600 UI/day then 600 UI/day 600 UI/day as induction therapy for 4 weeks, then 600 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)).

    Drug: vitamin D3

Interventions

  • DrugCholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3000 or 4000 UI/ day: Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance. Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance 600 UI/ day: Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance. Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance

    Also known as: cholecalciferol

06

What researchers measure

Primary outcomes

  1. Relapse

    A relapse is defined as the occurrence of clinical symptoms (\> 2 bowel movements per day, abdominal pain, fever, weight loss, perianal disease or extra-intestinal symptoms) and a pediatric Crohn's disease Activity Index (PCDAI) less than 10. The PCDAI is a validated and reproducible tool that was developed by consensus at a meeting of pediatric (Inflammatory bowel disease) IBD experts and subsequently validated in 12 North American institutions. It includes 11 domains, with clinical symptoms, physical examination, laboratory parameters, and growth. The PCDAI score can range from 0-100, with higher scores signifying more active disease. A score \< 10 is consistent with inactive disease; 11-30 indicates mild disease; \> 30 suggests moderate to severe disease. The PCDAI has been used in many pediatric trials.

    Time frame: Within 52 weeks after randomization in the study

Secondary outcomes

  1. Lapse of time from randomization to first relapse

    numbers of days between the randomisation and the first relapse

    Time frame: From date of randomization until the date of first relapse, assessed up to 52 weeks after randomization in the study

  2. Number of relapses per patient per year

    numbers of relapses during the entire study

    Time frame: Within 52 weeks after randomization in the study

  3. Number of hospitalizations per year

    numbers of hospitalizations during the entire study

    Time frame: Between randomization and Week 52

  4. Improvement of the Quality of life

    As measured by the IMPACT III questionnaire. IMPACT III is a validated questionnaire that assesses disease-related quality-of-life in multiple domains of care in pediatric IBD (bowel symptoms; systemic symptoms; emotional functioning; functional/social impairment; body image; test-treatments). Overall scores for IMPACT III range from 35 to 175 with higher scores associated with better quality of life

    Time frame: At week 26 and week 52

Other outcomes

  1. Change in the level of physical activities

    As measured by the Canadian Health Measures Survey - Children's Physical Activity. It includes 35 short questions. This is a questionnaire that has already been used by Canadian children. The responses will be converted into metabolic equivalents of tasks (METS) by using validated tables. Any activity ≥ 3 METS will be classified as moderate-to-vigorous physical activity

    Time frame: Between randomization and 52 weeks

07

Study locations

7 sites
  • Stollery Children's Hospital
    Edmonton, Alberta T6G 1C9, Canada
  • BC Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • Children's Hospital
    Winnipeg, Manitoba R3A 1S1, Canada
  • McMaster University
    Hamilton, Ontario L8N 3Z5, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Montreal Children's Hospital
    Montreal, Quebec H3H 1P3, Canada
  • CHU Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
08

References and documents

Publications

  • Jantchou, P., Mailhot, G., Ezri, J., Le Deist, F., Deslandres, C., & Delvin, E. (2014). P-102: Bioavailability and tolerance of high doses vitamin D in children with newly diagnosed Crohn's disease. Journal of Crohn's and Colitis, 8, S432. doi:10.1016/s1873-9946(14)50130-4
  • Jantchou P, Clavel-Chapelon F, Racine A, Kvaskoff M, Carbonnel F, Boutron-Ruault MC. High residential sun exposure is associated with a low risk of incident Crohn's disease in the prospective E3N cohort. Inflamm Bowel Dis. 2014 Jan;20(1):75-81. doi: 10.1097/01.MIB.0000436275.12131.4f. PubMed 24247650 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2020 to primary completion in Sep 2023, 43 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Dec 2023 → Sep 2023 and completion Dec 2024 → Sep 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2019
First posted
Jun 26, 2019
StartActual
Feb 7, 2020
Primary completionActual
Sep 29, 2023was Dec 2023
CompletionActual
Sep 29, 2023was Dec 2024
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated Enrollment stopped at 55 of 316 planned participants due to recruitment challenges related to the COVID-19 pandemic and funding constraints. All enrolled participants completed 52-week follow-up.
changed Oct 21, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Canada)
  • Montreal Children's Hospital · Montreal, Canada
  • CHU Sainte-Justine · Montreal, Canada
Show 2 removed
  • Montreal Children's Hospital · Montréal, Canada
  • CHU Sainte-Justine · Montréal, Canada
Oct 21, 2026
Primary completion
Dec 2023→Sep 29, 2023 (actual)
Oct 21, 2026
Study completion
Dec 2024→Sep 29, 2023 (actual)
Oct 21, 2026
Enrollment
316 (estimated)→55 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Status unknown→Terminated
    Why stopped Enrollment stopped at 55 of 316 planned participants due to recruitment challenges related to the COVID-19 pandemic and funding constraints. All enrolled participants completed 52-week follow-up.
    2 sites added, 2 sites removed
    Show 2 added (2 Canada)
    • Montreal Children's Hospital · Montreal, Canada
    • CHU Sainte-Justine · Montreal, Canada
    Show 2 removed
    • Montreal Children's Hospital · Montréal, Canada
    • CHU Sainte-Justine · Montréal, Canada
    Primary completion Dec 2023→Sep 29, 2023 (now actual)
    Study completion Dec 2024→Sep 29, 2023 (now actual)
    Enrollment 316 (estimated)→55 (actual)
    + 4 other changes: verification date, responsible party, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03999580
Lead sponsor
Jantchou Prevost
Responsible party
Jantchou Prevost (Professor of Pediatrics, St. Justine's Hospital) — Sponsor-investigator
First posted
Jun 26, 2019
Start date
Feb 7, 2020
Primary completion
Sep 29, 2023
Completion
Sep 29, 2023
Last update
Oct 21, 2026

Study contacts

Prevost Jantchou, MD,PhD
principal investigator · St. Justine's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cholecalciferol

Start the discussion